Molecular biomarkers in drug development

Drug Discovery Today

Volumn 9, Issue 22, 2004, Pages 976-983

  Lewin, David A ^a   Weiner, Michael P ^b  

^a CURAGEN CORPORATION   (United States)

^b Rothberg Institute for Childhood Diseases   (United States)

Author keywords

Drug Discovery; genomics; pharmacogenomics; preclinical and clinical development; proteomics

Indexed keywords

BIOLOGICAL MARKER;

CHEMICAL ANALYSIS; DNA MICROARRAY; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG INDUSTRY; GEL ELECTROPHORESIS; GENE EXPRESSION PROFILING; INFORMATION RETRIEVAL; ISOTOPE ANALYSIS; MEDICAL DECISION MAKING; PATIENT SATISFACTION; PHARMACOGENOMICS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA SPLICING; RNA STABILITY; RNA TRANSPORT; STATISTICAL SIGNIFICANCE;

ANIMALS; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; NUCLEIC ACIDS; PROTEINS; PROTEOMICS;

EID: 7944238046     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03272-6     Document Type: Review

References (54)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69:2001;89-95
2. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2:2003;566-580
3. Evans S.M., Koch C.J. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 195:2003;1-16
4. Mildvan D., et al. An approach to the validation of markers for use in AIDS clinical trials. Clin. Infect. Dis. 24:1997;764-774
5. Lesko, L. et al. (2003) Guidance for Industry: Pharmacogenomic Data Submissions. U.S. Department of Health and Human Services, Food and Drug Administration, CDER, CBER, CDRH. http://www.fda.gov/cder/guidance/5900dft.pdf
6. Caldwell G.W., et al. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr. Top. Med. Chem. 1:2001;353-366
7. Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. J. Hepatol. 26:(Suppl 2):1997;26-36
8. Olson H., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32:2000;56-67
9. Lindpaintner K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1:2002;463-469
10. Lakkis M.M., et al. Application of toxicogenomics to drug development. Expert Rev. Mol. Diagn. 2:2002;337-345
11. Ulrich R., Friend S.H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat. Rev. Drug Discov. 1:2002;84-88
12. Ellinger-Ziegelbauer H., et al. Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol. Sci. 77:2003;19-34
13. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:2001;3-26
14. Gunther E.C., et al. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc. Natl. Acad. Sci. U. S. A. 100:2003;9608-9613
15. Ye S.Q., et al. Gene expression profiling of human diseases by serial analysis of gene expression. J. Biomed. Sci. 9:2002;384-394
16. Strausberg R.L., et al. An international database and integrated analysis tools for the study of cancer gene expression. Pharmacogenomics J. 2:2002;156-164
17. Porter D.A., et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 61:2001;5697-5702
18. Carulli J.P., et al. High throughput analysis of differential gene expression. J. Cell. Biochem. Suppl. 1998;30-31. 286-296
19. Green C.D., et al. Open systems: panoramic views of gene expression. J. Immunol. Methods. 250:2001;67-79
20. Velculescu V.E., et al. Serial analysis of gene expression. Science. 270:1995;484-487
21. Boon K., Riggins G.J. SAGE as a strategy to isolate cancer-related genes. Methods Mol. Biol. 222:2003;463-479
22. Mei R., et al. Probe selection for high-density oligonucleotide arrays. Proc. Natl. Acad. Sci. U. S. A. 100:2003;11237-11242
23. Fodor S.P., et al. Multiplexed biochemical assays with biological chips. Nature. 364:1993;555-556
24. Pease A.C., et al. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5022-5026
25. Lipshutz R.J., et al. Using oligonucleotide probe arrays to access genetic diversity. BioTechniques. 19:1995;442-447
26. Pollock J.D. Gene expression profiling: methodological challenges, results, and prospects for addiction research. Chem. Phys. Lipids. 121:2002;241-256
27. Gnatenko D.V., et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood. 101:2003;2285-2293
28. Nimgaonkar A., et al. Reproducibility of gene expression across generations of Affymetrix microarrays. BMC Bioinformatics. 4:2003;27
29. Heid C.A., et al. Real time quantitative PCR. Genome Res. 6:1996;986-994
30. Kang J.J., et al. Transcript quantitation in total yeast cellular RNA using kinetic PCR. Nucleic Acids Res. 28:2000;e2
31. Ge H., et al. Integrating 'omic' information: a bridge between genomics and systems biology. Trends Genet. 19:2003;551-560
32. Kiechle F.L., Holland-Staley C.A. Genomics, transcriptomics, proteomics, and numbers. Arch. Pathol. Lab. Med. 127:2003;1089-1097
33. Voshol H., et al. Proteomics in the discovery of new therapeutic targets for psychiatric disease. Curr. Mol. Med. 3:2003;447-458
34. He Q.Y., Chiu J.F. Proteomics in biomarker discovery and drug development. J. Cell. Biochem. 89:2003;868-886
35. Petricoin E.F., Liotta L.A. Clinical applications of proteomics. J. Nutr. 133:(Suppl):2003;2476S-2484S
36. Phizicky E., et al. Protein analysis on a proteomic scale. Nature. 422:2003;208-215
37. Patterson S.D., Aebersold R.H. Proteomics: the first decade and beyond. Nat. Genet. 33:(Suppl):2003;311-323
38. Sellers T.A., Yates J.R. Review of proteomics with applications to genetic epidemiology. Genet. Epidemiol. 24:2003;83-98
39. Zhu H., et al. Proteomics. Annu. Rev. Biochem. 72:2003;783-812
40. Hunter T.C., et al. The functional proteomics toolbox: methods and applications. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 782:2002;165-181
41. Michaud G.A., Snyder M. Proteomic approaches for the global analysis of proteins. BioTechniques. 33:2002;1308-1316
42. Han D.K., et al. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat. Biotechnol. 19:2001;946-951
43. Smolka M.B., et al. Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Anal. Biochem. 297:2001;25-31
44. Gygi S.P., et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17:1999;994-999
45. Unlu M., et al. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis. 18:1997;2071-2077
46. Tonge R., et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics. 1:2001;377-396
47. Kononen J., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4:1998;844-847
48. Kallioniemi O.P., et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum. Mol. Genet. 10:2001;657-662
49. Camp R.L., et al. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80:2000;1943-1949
50. Dhanasekaran S.M., et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 412:2001;822-826
51. Fejzo M.S., Slamon D.J. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am. J. Pathol. 159:2001;1645-1650
52. Raamsdonk L.M., et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol. 19:2001;45-50
53. Birner P., et al. Evaluation of the United States Food and Drug Administration approved scoring and test system of HER-2 protein expression in breast cancer. Clin. Cancer Res. 7:2001;1669-1675
54. Harvey R. The judgment of urines. CMAJ. 159:1998;1482-1484